{
    "clinical_study": {
        "@rank": "68779", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in\n      combination with fluoropyrimidine-based chemotherapy in elderly patients (>/= 65 years of\n      age) with newly diagnosed metastatic colorectal cancer. Patients will be followed until\n      disease progression, death, withdrawal of consent, discontinuation of physician-patient\n      relationship or study closure, whichever comes first."
        }, 
        "brief_title": "BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 65 years of age\n\n          -  Patients with newly diagnosed metastatic colorectal cancer starting first-line\n             treatment with Avastin in combination with fluoropyrimidine-based chemotherapy\n             according to the approved Hungarian Summary of Product Characteristics\n\n          -  Patients suitable for Avastin treatment as assessed by the treating physician\n\n        Exclusion Criteria:\n\n          -  Any contraindications to Avastin treatment according to the Hungarian Summary of\n             Product Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Elderly patients (</= 65 years of age) with newly diagnosed metastatic colorectal cancer\n        starting first-line treatment with Avastin in combination with fluoropyrimidine-based\n        chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791140", 
            "org_study_id": "ML25630"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Budapest", 
                    "country": "Hungary", 
                    "zip": "1145"
                }
            }
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_groups": "1", 
        "official_title": "Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Hungary: Medical Research Council"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Median progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "approximately 3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate (complete response + partial response)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Clinical benefit rate (complete response + partial response + stable disease)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Metastasectomy rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Mean duration of Avastin treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Median progression-free survival in subgroup receiving Avastin plus fluorouracil monotherapy", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Median progression-free survival according to age group (65-74 years; >/= 75 years)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}